Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study - PubMed (original) (raw)
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study
Muhammad A Abdul-Ghani et al. Diabetes. 2006 May.
Abstract
This study was conducted to observe changes in insulin secretion and insulin action in subjects with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). A total of 319 subjects were studied with an oral glucose tolerance test (OGTT). Fasting plasma glucose and insulin concentrations were measured at baseline and every 30 min during the OGTT. Fifty-eight subjects also received a euglycemic-hyperinsulinemic clamp. Insulin sensitivity was calculated as the total glucose disposal (TGD) during the last 30 min of the clamp. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from fasting plasma glucose and insulin concentrations. Subjects with IFG had TGD similar to normal glucose-tolerant subjects, while subjects with IGT and combined IFG/IGT had significantly reduced TGD. HOMA-IR in subjects with IFG was similar to that in subjects with combined IFG/IGT and significantly higher than HOMA-IR in subjects with IGT or NGT. Insulin secretion, measured by the insulinogenic index (DeltaI(0-30)/DeltaG(0-30)) and by the ratio of the incremental area under the curve (AUC) of insulin to the incremental AUC of glucose (0-120 min), was reduced to the same extent in all three glucose-intolerant groups. When both measurements of beta-cell function were adjusted for severity of insulin resistance, subjects with IGT and combined IFG/IGT had a significantly greater reduction in insulin secretion than subjects with IFG. Subjects with IGT and IFG have different metabolic characteristics. Differences in insulin sensitivity and insulin secretion may predict different rates of progression to type 2 diabetes and varying susceptibility to cardiovascular disease.
Similar articles
- Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose.
Kanat M, Norton L, Winnier D, Jenkinson C, DeFronzo RA, Abdul-Ghani MA. Kanat M, et al. Acta Diabetol. 2011 Sep;48(3):209-17. doi: 10.1007/s00592-011-0285-x. Epub 2011 May 8. Acta Diabetol. 2011. PMID: 21553243 Clinical Trial. - Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects.
Miyazaki Y, Akasaka H, Ohnishi H, Saitoh S, DeFronzo RA, Shimamoto K. Miyazaki Y, et al. Hypertens Res. 2008 Jul;31(7):1357-63. doi: 10.1291/hypres.31.1357. Hypertens Res. 2008. PMID: 18957806 - Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.
Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE; American Diabetes Association GENNID Study Group. Jensen CC, et al. Diabetes. 2002 Jul;51(7):2170-8. doi: 10.2337/diabetes.51.7.2170. Diabetes. 2002. PMID: 12086947 - Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose.
Abdul-Ghani MA, Tripathy D, DeFronzo RA. Abdul-Ghani MA, et al. Diabetes Care. 2006 May;29(5):1130-9. doi: 10.2337/diacare.2951130. Diabetes Care. 2006. PMID: 16644654 Review. - NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse.
McGuinness OP, Ayala JE, Laughlin MR, Wasserman DH. McGuinness OP, et al. Am J Physiol Endocrinol Metab. 2009 Oct;297(4):E849-55. doi: 10.1152/ajpendo.90996.2008. Epub 2009 Jul 28. Am J Physiol Endocrinol Metab. 2009. PMID: 19638507 Free PMC article. Review.
Cited by
- Etiologies underlying subtypes of long-standing type 2 diabetes.
Bayoumi R, Farooqi M, Alawadi F, Hassanein M, Osama A, Mukhopadhyay D, Abdul F, Sulaiman F, Dsouza S, Mulla F, Ahmed F, AlSharhan M, Khamis A. Bayoumi R, et al. PLoS One. 2024 May 28;19(5):e0304036. doi: 10.1371/journal.pone.0304036. eCollection 2024. PLoS One. 2024. PMID: 38805513 Free PMC article. - Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes.
Martínez-López YE, Neri-Rosario D, Esquivel-Hernández DA, Padron-Manrique C, Vázquez-Jiménez A, Sánchez-Castañeda JP, Girón-Villalobos D, Mendoza-Ortíz C, Reyes-Escogido ML, Evia-Viscarra ML, Aguilar-Garcia A, Resendis-Antonio O, Guardado-Mendoza R. Martínez-López YE, et al. Sci Rep. 2024 Apr 27;14(1):9678. doi: 10.1038/s41598-024-60081-y. Sci Rep. 2024. PMID: 38678119 Free PMC article. - Zinc Alpha-2 Glycoprotein, Acylated Ghrelin, and Zinc Levels in Prediabetics.
Kurtuluş EM, Kariş D, Ercan AM, Konukoğlu D. Kurtuluş EM, et al. In Vivo. 2024 Mar-Apr;38(2):975-981. doi: 10.21873/invivo.13530. In Vivo. 2024. PMID: 38418147 Free PMC article. - The Effects of a High-Carbohydrate versus a High-Fat Shake on Biomarkers of Metabolism and Glycemic Control When Used to Interrupt a 38-h Fast: A Randomized Crossover Study.
Deru LS, Gipson EZ, Hales KE, Bikman BT, Davidson LE, Horne BD, LeCheminant JD, Tucker LA, Bailey BW. Deru LS, et al. Nutrients. 2024 Jan 4;16(1):164. doi: 10.3390/nu16010164. Nutrients. 2024. PMID: 38201992 Free PMC article. Clinical Trial. - DXA-based Fat Mass With Risk of Worsening Insulin Resistance in Adolescents: A 9-Year Temporal and Mediation Study.
Agbaje AO, Saner C, Zhang J, Henderson M, Tuomainen TP. Agbaje AO, et al. J Clin Endocrinol Metab. 2024 Aug 13;109(9):e1708-e1719. doi: 10.1210/clinem/dgae004. J Clin Endocrinol Metab. 2024. PMID: 38173399 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical